Novo nabs Cardior in €1B deal, gaining phase II-stage miRNA drug | BioWorld
… disease-modifying heart failure candidate in the hands of a big pharma player in the midst of establishing its presence in cardiovascular disease.
… disease-modifying heart failure candidate in the hands of a big pharma player in the midst of establishing its presence in cardiovascular disease.